Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Director/PDMR Shareholding

4 Oct 2010 09:45

RNS Number : 7863T
Allergy Therapeutics PLC
04 October 2010
 



Allergy Therapeutics PLC

4 October 2010

 



Monday 4 October 2010

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Major Shareholdings/Holding by Director

 

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specializing in allergy vaccines announces today that 137,491,788 of its ordinary shares were transferred on 28 September 2010 by Azure Ventures Limited to Yissum Holdings Limited a company controlled by members of the Weinstein family, including Mr Alejandro Weinstein Jr, a non-executive director of the Company. Notification of the transfer was received by the Company on 4 October 2010. There has been no change in the aggregate beneficial holding of shares in the Company by the Weinstein family.

 

 

The Karjiang Pharma Trust, of which the Weinstein family, including Mr Alejandro Weinstein Jr., are beneficiaries, continues to hold 3,076,499 shares in the Company, through Azure Ventures Limited. As a result of the transfer the percentage of voting rights controlled by the Karjiang Pharma Trust has fallen from 45.23 per cent. to below 3 per cent.

 

Yissum Holdings Limited, a company which is controlled by the Weinstein family, including Mr Alejandro Weinstein Jr., now holds 137,491,788 shares in the Company, representing 44.24 per cent. of the Company's total voting rights.

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Christopher Golden

www.nomuracode.com

 

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGIBDGXSGBGGS
Date   Source Headline
8th Mar 20217:00 amRNSAGY to Present at H.C. Wainwright Conference
3rd Mar 20217:00 amRNSInterim Results for six months ended 31 Dec 2020
15th Jan 20217:00 amRNSBlock Listing Return and Total Voting Rights
13th Jan 20217:00 amRNSHalf Year Trading Update 2021 & Notice of Results
8th Jan 20214:41 pmRNSSecond Price Monitoring Extn
8th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSInitiation of peanut allergy biomarker study
14th Dec 20203:58 pmRNSDirector/PDMR Shareholding
8th Dec 20202:42 pmRNSResult of Annual General Meeting
20th Nov 20201:51 pmRNSGrant of Awards under Long Term Incentive Plan
20th Nov 20207:00 amRNSDirector/PDMR Shareholding
10th Nov 20207:05 amRNSAnnual Report & Accounts and AGM Notification
26th Oct 20207:00 amRNSInitiation of Grass MATA MPL exploratory study
12th Oct 20207:00 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSDirector Dealings and Issue of Equity
23rd Sep 20207:00 amRNSPreliminary Results
3rd Sep 20207:00 amRNSAGY secures VLP technology platform
20th Jul 20207:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15th Jul 202011:05 amRNSSecond Price Monitoring Extn
15th Jul 202011:00 amRNSPrice Monitoring Extension
15th Jul 20207:00 amRNSTrading Update
9th Jul 20207:00 amRNSInvalidation of Birch MATA MPL phase III results
1st Jul 20205:15 pmRNSTotal Voting Rights
1st Jul 20205:14 pmRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:36 pmRNSPrice Monitoring Extension
24th Jun 20207:00 amRNSTrading Update
18th May 20202:05 pmRNSSecond Price Monitoring Extn
18th May 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:36 pmRNSPrice Monitoring Extension
22nd Apr 202010:11 amRNSEAACI review of adjuvants and formulations
1st Apr 20201:09 pmRNSGrant and Vesting of Awards
9th Mar 20207:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
4th Mar 20207:00 amRNSHalf-year Report
29th Jan 202012:00 pmRNSData for peanut allergy vaccine published in JACI
16th Jan 202012:25 pmRNSTrading Update & Notice of Results - Replacement
16th Jan 20208:00 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16th Jan 20207:00 amRNSHalf Year Trading Update & Notice of Results
2nd Dec 20199:57 amRNSHoldings in Company
29th Nov 201910:34 amRNSHoldings in Company
26th Nov 20197:00 amRNSUpdate to Grass MATA MPL Ph III clinical programme
25th Nov 201912:13 pmRNSResult of Annual General Meeting
22nd Oct 20199:23 amRNSAnnual Report and Accounts
26th Sep 20197:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25th Sep 20197:00 amRNSPreliminary Results
11th Jul 20197:00 amRNSTrading update
1st Jul 20197:21 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
1st Jul 20197:16 amEQSHardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27th Jun 20197:00 amRNSSuccessful Litigation Settlement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.